search

Full List of Publications

E-mail Print PDF

Foster Lab Publications:

 

1.       Foster DA, Spangler R, and Zubay G. (1981). Inhibition of host DNA synthesis by adenovirus infection is reversed at elevated temperatures. J. Virol. 37, 493-495. PMCID: PMC171027

2.       Foster DA. (1981). 1-ß-D-Arabinosylcytosine stimulates thymidine incorporation into the DNA of contact-inhibited cells. Exp. Cell Res. 135, 427-431.

3.       Foster DA, Hantzopoulos P, and Zubay G. (1982). Resistance of adenoviral DNA replication to aphidicolin is dependent on the 72-kilodalton DNA-binding protein. J. Virol. 43, 679-686. PMCID: PMC256170

4.       Foster DA, and Hanafusa H. (1983). A fps gene without gag gene sequences transforms cells in culture and induces tumors in chickens. J. Virol. 48, 744-751. PMCID: PMC255406

5.       Foster DA, Shibuya M, and Hanafusa H. (1985).  Activation of the transformation potential of the cellular-fps gene.  Cell. 42, 105-115. PMCID: PMC367515

6.       Foster DA, Levy JB, Daley GQ, Simon MC, and Hanafusa H. (1986). Isolation of chicken cellular DNA sequences with homology to the region of viral oncogenes that encodes the tyrosine kinase domain.  Mol. Cell. Biol. 6, 325-331.

7.       Spangler R, Joseph C, Qureshi S, Berg KL, and Foster DA. (1989). Evidence that v-src and v-fps gene products use a protein kinase C-mediated pathway to induce expression of a transformation-related gene.  Proc. Natl. Acad. Sci. USA 86, 7017-7021. PMCID: PMC297983

8.       Qureshi SA, Alexandropoulos K, Joseph CK, Spangler R, and Foster DA. (1991). Cholera toxin induces expression of the immediate-early response gene, JE, via a cAMP-independent signaling pathway.  Mol. Cell. Biol. 11, 102-107. PMCID: PMC359597

9.       Qureshi SA, Joseph CK, Rim M-H, Maroney A, and Foster DA. (1991). v-Src Activates Both Protein Kinase C-Dependent and Independent Signaling Pathways in Murine Fibroblasts. Oncogene. 6, 995-999.

10.    Qureshi SA, Cao X, Sukhatme VP, and Foster DA. (1991). v-Src Activates Mitogen-responsive Transcription Factor Egr-1 via Serum Response Elements. J. Biol. Chem. 266, 10802-10806.

11.    Alexandropoulos K, Joseph CK, Spangler R, and Foster DA. (1991).  Evidence for the Involvement of a G-Protein in signals initiated by the protein-tyrosine kinase v-Fps.  J. Biol. Chem. 266, 15583-15586.

12.    Song J, Pfeffer LM, and Foster DA. (1991). v-Src Increases Diacylglycerol levels via a yype D phospholipase-mediated hydrolysis of phosphatidylcholine. Mol. Cell. Biol. 11, 4903-4908. PMCID: PMC361459

13.    Qureshi SA, Rim M, Bruder J, Kolch W, Rapp U, Sukhatme VP, and Foster DA. (1991). An inhibitory mutant of c-Raf-1 blocks v-Src-induced activation of the Egr-1 promoter. J. Biol. Chem. 266, 20594-20597.

14.    Qureshi SA, Rim M, Alexandropoulos K, Berg K, Sukhatme VP, and Foster DA. (1992). Sustained induction of Egr-1 by v-Src correlates with a lack of Fos-mediated repression of the Egr-1 promoter.  Oncogene. 7, 121-125.

15.    Joseph CK, Qureshi SA, Wallace DW, and Foster DA. (1992). MARCKS protein is transcriptionally down-regulated in v-Src-transformed BALB/c 3T3 cells.  J. Biol. Chem. 267, 1327-1330.

16.    Alexandropoulos K, Qureshi SA, Sukhatme VP, and Foster DA. (1992). v-Fps-responsiveness in the Egr-1 promoter is mediated by serum response elements. Nuc. Acid Res. 9, 2355-2359. PMCID: PMC312353

17.    Maroney AC, Qureshi SA, Foster DA, and Brugge JS. (1992). Cloning and characterization of a thermolabile v-src gene for use in reversible transformation of mammalian cells. Oncogene 7, 1207-1214.

18.    Rim M, Qureshi SA, Gius D, Nho J, Sukhatme VP, and Foster DA. (1992). v-Raf activates the Egr-1 promoter through serum response elements. Oncogene. 7, 2065-2068.

19.    Qureshi SA, Alexandropoulos K, Joseph CK, Rim M, Bruder J, Rapp UR, and Foster DA. (1992).  Evidence that HaRas mediates two distinct intracellular signals activated by v-Src. J. Biol. Chem. 267, 17635-17639.

20.    Alexandropoulos K, Qureshi SA, Bruder J, Rapp UR, and Foster DA. (1992). The induction of the Egr-1 promoter by v-Fps is via a PKC-independent intracellular signal that is sequentially dependent upon HaRas and Raf-1.  Cell Growth and Differ. 3, 731-737.

21.    Alexandropoulos K, Qureshi SA, and Foster DA. (1993). HaRas functions downstream from protein kinase C in v-Fps-induced gene expression mediated by TPA response elements. Oncogene. 8, 803-807.

22.    Qureshi SA, Joseph CK, Gupta R, Hendrickson M, Song J, Bruder J, Rapp U, and Foster DA. (1993). A dominant-negative Raf-1 mutant prevents v-Src-induced transformation. Biochem. Biophys. Res. Comm. 192, 969-975. 

23.    Foster DA. (1993). Intracellular signalling mediated by protein-tyrosine kinases:  Networking through phospholipid metabolism.  Cell. Signalling. 5, 389-399. 

24.    Song J, and Foster DA. (1993). v-Src activates a phospholipase D activity that is distinguishable from phospholipase D activity activated by protein kinase C. Biochem. J. 294, 711-717.  PMCID: PMC1134521

25.    Gupta, R., Joseph, C.K., and Foster, D.A. (1993). v-Src-induced transformation is inhibited by okadaic acid.  Biochem. Biophys. Res. Comm. 196, 320-327.

26.    Song J, Jiang Y-W, and Foster DA. (1994). EGF induces the production of biologically distinguishable diglyceride species from phosphatylinositol and phosphatidylcholine: Evidence for the independent activation of type C and type D phospholipases.  Cell Growth and Differ. 5, 79-85.

27.    Chao T-SO, Foster DA, Rapp UR, and Rosner MR. (1994). Differential Raf-1 requirement for activation of mitogen-activated protein kinase by growth factors, phorbol esters and calcium. J. Biol. Chem. 269, 7337-7341.

28.    Jiang H, Alexandropoulos K, Song J, and Foster DA. (1994). Evidence that v-Src-induced phospholipase D activity is mediated by a G-protein. Mol. Cell. Biol. 14, 3676-3682. PMCID: PMC358735

29.    Jiang Y-W, Song J, Zang Q, and Foster DA. (1994). Phosphatidylcholine-specific phospholipase D activity is elevated in v-Fps-transformed cells. Biochem. Biophys. Res. Comm. 203,1195-1203

30.    Gupta R, and Foster DA. (1994).  Differential effects of protein phosphatase 2A on distinguishable intracellular signals initiated by v-Src and mediated by HaRas.  Biochem. Biophys. Res. Comm. 205, 1043-1050.

31.    Jiang H, Lu Z, Luo JQ, Wolfman A, and Foster DA. (1995). Ras mediates the activation of phospholipase D by v-Src. J. Biol. Chem. 270, 6006-6009.    

32.    Mukhopadhyay D, Tsiokas L, Zhou XM, Foster DA, Brugge JS, and Sukhatme VP. (1995). Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature. 375, 577-580.

33.    Zang Q, Frankel P, and Foster DA. (1995). Selective activation of protein kinase C isoforms in v-Src-transformed BALB/c 3T3 cells. Cell Growth Differ. 6, 1367-1373.   

34.    Jiang H, Luo JQ, Urano T, Frankel P, Lu Z, Foster DA*, and Feig LA. (1995). Involvement of Ral GTPase in v-Src-induced Phospholipase D activation. Nature. 378, 409-412. (*Corresponding author).

35.    Spiegel S, Foster DA. and Kolesnick R. (1996). Signal transduction through lipid second messengers. Curr. Op. Cell Biol. 8, 159-167.

36.    Jiang YW, Lu Z, Zang Q, and Foster DA. (1996). Regulation of phosphatidic acid phosphohydrolase by EGF: Reduced association with the EGF receptor followed by increased association with protein kinase Ce. J. Biol. Chem. 271, 29529-29532.

37.    Zang Q, Lu Z, Curto M, Barile N, Shalloway D, and Foster DA. (1997). Interaction between v-Src and protein kinase Cd in v-Src-transformed fibroblasts. J. Biol. Chem. 272, 13275-13280.

38.    Lu Z, Hornia A, Jiang YW, Frankel P, Zang Q, Ohno S, and Foster DA. (1997). Tumor-promotion by depleting cells of protein kinase Cd. Mol. Cell Biol.. 17, 3418-3428. PMCID: PMC232195

39.    Luo JQ, Liu X, Hammond SM, Colley WC, Feig LA, Frohman MA. Morris AJ, and Foster DA. (1997). Ral interacts directly with the Arf-responsive PIP2-dependent phospholipase D1. Biochem. Biophys. Res. Comm. 235, 854-859.

40.    Curto M, Carrero A, Frankel P, and Foster DA. (1997). Activation of gene expression by a non-transforming unmyristylated-SH3-deleted mutant of Src is dependent upon Tyr-527. Biochem. Biophys. Res. Comm. 239, 681-687.

41.    Lu, Z., Liu, D., Hornia, A., Devonish, W., Pagano, M., and Foster, D.A. (1998). Activation of protein kinase C triggers its ubiquitination and degradation. Mol. Cell. Biol. 18, 839-845. PMCID: PMC108795

42.    Curto, M., Frankel, P., Carrero, A., and Foster, D.A. (1998). Novel recruitment of Shc, Grb2, and Sos by fibroblast growth factor receptor-1 in v-Src-transformed cells.  Biochem. Biophys. Res. Comm. 243, 555-560.

43.    Luo, J.-Q., Liu, X., Frankel, P., Rotunda, T., Ramos, M., Flom, J., Jiang, H., Feig, L.A., Morris, A, Kahn, R.A. and Foster, D.A. (1998). Functional association between RalA and Arf in active phospholipase D complexes. Proc. Natl. Acad. Sci. USA. 95, 3632-3637. PMCID: PMC19887

44.    Frankel, P.A., Ramos, M., Flom, J., Bychenok, S., Joseph, T., Kerkhoff, E., Rapp, U.R., Feig, L.A., and Foster, D.A. (1999). Ral and Rho dependent activation of phospholipase D in v-Raf transformed cells. Biochem. Biophys. Res. Comm. 255, 502-507.

45.    Corbit, K.C., Foster, D.A., Rosner, M.R. (1999). PKC d mediates neurogenic, but not mitogenic activation of MAP kinase in neuronal cells. Mol. Cell. Biol. 19, 4209-4218. PMCID: PMC104380

46.    Aguirre Ghiso, J., Frankel, P., Lu, Z., Jiang, H., Farias, E., Olsen, A., Feig, L.A., Bal de Kier Joffe, E., and Foster, D.A. (1999). RalA requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator and metalloproteases. Oncogene 18, 4718-4725. 

47.    Hornia, A., Lu, Z., Sukezane, T., Zhong, M. Joseph, T., Frankel, P., and Foster, D.A.  (1999). Antagonistic effects of protein kinase Ca and d on both transformation and phospholipase D activity mediated by the EGF receptor. Mol. Cell. Biol. 19, 7672-7680. PMCID: PMC84804

48.    Lu, Z., Hornia, A., Joseph, T., Sukezane, T., Frankel, P., (Zhong et al., 2003), M., Bychenok, S., Xu, L., Feig, L.A., and Foster, D.A. (2000). Phospholipase D and RalA cooperate with the EGF receptor to transform 3Y1 rat fibroblasts. Mol. Cell. Biol. 20, 462-467. PMCID: PMC85102

49.    Goi, T., Shipistin, M., Lu, Z., Foster, D.A., Klinz, S.G., and Feig, L.A. (2000). An EGF receptor/Ral-GTPase signaling cascade regulates c-Src activity and substrate specificity. EMBO J. 19, 623-630. PMCID: PMC305600

50.  Bychenok, S., and Foster D.A. (2000). A low MW factor from dividing cells activates phospholipase D in caveolin-enriched membrane microdomains. Arch. Biochem. Biophys. 377, 139-145.

51.  Xu, L., Shen, Y., Joseph, T., Luo, J.-Q., Frankel, P., Rotunda, T., and Foster, D.A. (2000). Elevated phospholipase D activity in transformed cells is restricted to caveolin-enriched membrane microdomains: Biochem. Biophys. Res. Comm. 273, 77-83.

52.  Shen, Y., Xu, L., and Foster, D.A. (2001). Role for phospholipase D in receptor-mediated endocytosis. Mol. Cell. Biol. 21, 595-602. PMCID: PMC86627

53.   Zhong, M., Lu, Z., Abbas, T. Hornia, A., Chatakondu, K., Barile, N., Kaplan, P., and Foster, D.A. (2001). Novel tumor-promoting property of tamoxifen.  Cell Growth Differ. 12, 187-192.

54.   Ladeda, V., Frankel P., Feig, L.A., Foster, D.A., Bal de Kier Joffe, E., and Aguirre-Ghiso, J.A. (2001). RalA mediates v-Src, v-Ras and v-Raf regulation of CD44 and fibronectin expression in NIH3T3 fibroblasts. Biochem. Biophys. Res. Comm. 283, 854-861.

55.   Joseph, T., Wooden, R., Bryant, A., Zhong, M., Lu, Z., and Foster, D.A. (2001). Transformation of cells overexpressing a tyrosine kinase by phospholipase D1 and D2. Biochem. Biophys. Res. Comm. 289, 1019-1024.

56.   Zhong, M., Lu, Z., and Foster, D.A. (2002). Downregulating PKCd provides a PI3K/Akt-independent survival signal that overcomes apoptotic signals generated by c-Src overexpression. Oncogene 21, 1071-1078.

57.  Joseph, T., Bryant, A., Wooden, R., Kerkhoff, E., Rapp, U.R. and Foster, D.A. (2002). Phospholipase D overcomes cell cycle arrest induced by high-intensity Raf signaling. Oncogene 21, 3651-3658.

58.  Shen, Y., Zheng, Y., and Foster, D.A. (2002). Phospholipase D2 stimulates cell protrusion in v-Src-transformed cells. Biochem. Biophys. Res. Comm. 293, 201-206.

59.  Zhong, M., Joseph, T., Jackson, D., Beychenok, S., and Foster, D.A. (2002) Elevated phospholipase D induces apoptosis in normal rat fibroblasts. Biochem. Biophys. Res. Comm. 298, 474-477.

60.  Xu, L., Frankel, P., Jackson, D., Rotunda, T., Boshans, R.L., D’Souza-Schorey, C., and Foster, D.A. (2003). Elevated phospholipase D activity in H-Ras-, but not K-Ras-transformed cells by the synergistic action of RalA and Arf6. Mol. Cell. Biol. 23, 645-654. PMCID: PMC151535

61.  Zhong, M., Shen, Y., Zheng, Y., Joseph, T., Jackson, D., Beychenok, S., and Foster, D.A. (2003). Phospholipase D prevents apoptosis in v-Src-transformed rat fibroblasts and MDA-MB-231 breast cancer cells. Biochem. Biophys. Res. Comm. 302, 615-619.

62.  Chen, Y., Zheng, Y., and Foster, D.A. (2003). Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene. 22, 3937-3942.

63.  Foster, D.A. and Xu, L. (2003). Phospholipase D in cell proliferation and cancer. Mol. Cancer Res. 1, 789-800.

64.  Jackson, D., and Foster, D.A. (2004). The enigmatic protein kinase Cd: Complex roles in cell proliferation and survival. FASEB J. 18, 627-636.

65.  Abbas, T., White, D., Hui, L., Foster, D.A. and Jill Bargonetti, J. (2004). Inhibition of p53 transcription by down-regulation of protein kinase Cd. J. Biol. Chem. 279, 9970-9977.

66.  Hui, L., Abbas, T., Pielak, R., Joseph, T., Bargonetti, J. and Foster, D.A. (2004). Phospholipase D elevates the level of MDM2 and suppresses DNA damage-induced increases in p53.  Mol. Cell. Biol. 24, 5677-5688. PMCID: PMC480910

67.  Foster, D.A. (2004). Targeting mTOR-mediated survival signals in anticancer therapeutic strategies.  Exp. Rev. Anticancer Ther. 4, 691-701.

68.  Chen, X., Hui, L., Foster, D.A., and Drain, C.M. (2004). Efficient synthesis and photodynamic activity of porphyrin-saccharide conjugates: Targeting and incapacitating cancer cells. Biochemistry, 43, 10918-10929.

69.  Chen, Y., Rodrik, V. and Foster, D.A. (2005). Alternative phospholipase D / mTOR survival signal in human breast cancer cells. Oncogene, 24, 672-679.

70.  Jackson, D., Zheng, Y., Lyo, D., Shen, Y., Nakayama, K., Nakayama, K.I., Humphries, M., Reyland, M.E., and Foster, D.A. (2005).  Suppression of cell migration by protein kinase Cd. Oncogene. 24, 3067-3072.

71. Rodrik, V., Zheng, Y., Harrow, F., Chen, Y., and Foster, D.A. (2005). Survival signals generated by estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on Myc. Mol. Cell. Biol. 25, 7917-7925. PMCID: PMC1190308

72. Hui, L., Rodrik, V., Pielak, R.M., Zheng, Y., and Foster, D.A. (2005). mTOR-dependent suppression of protein phosphatase 2A is critical for phospholipase D survival signals in human breast cancer cells. J. Biol. Chem. 280, 35829-35835.

73. Cai,  D., Zhong, M.,  Wang, R., Netzer, W.J., Shields, D., Zheng, H., Sisodia, S.S., Foster, D.A., Gorelick, F.S., Xu, H., and Greengard, P. (2006). Phospholipase D1 corrects impaired βAPP trafficking and neurite outgrowth in FAD-linked PS1 mutant neurons. Proc. Natl. Acad. Sci. USA, 103, 1936-1940. PMCID: PMC1413666

74. Cai, D., Netzer, W.J., Zhong, M., Lin, Y., Guangwei Du, G., Frohman, M., Foster, D.A., Sisodia S.S., Xu, H., Gorelick, F.S., and Greengard, P. (2006). Presenilin-1 (PS1) utilizes phospholipase D1 as a negative regulator of β-amyloid formation. Proc. Natl. Acad. Sci. USA, 103, 1941-1946. PMCID: PMC1413665

75. Zheng, Y., Rodrik, V., Toschi, A., Shi, M., Hui. L., Shen, Y., and Foster, D.A. (2006). Phospholipase D couples survival and migration signals in response to stress in human breast cancer cells. J. Biol. Chem.  281, 15862-15868.

76.  Foster, D.A. (2006). Phospholipase D survival signals as a therapeutic target in cancer. Current Signal Transduction Ther. 1, 295-303.

77.  Rodrik, V., Gomes, E., Hui, L., Rockwell, P., and Foster, D.A. (2006). Myc stabilization in response to estrogen and phospholipase D in MCF-7 breast cancer cells. FEBS Lett. 580, 5647-5652. PMCID: PMC1876739

78.  Hui, L., Zheng, Y., Yan, Y., Bargonetti, J., and Foster, D.A. (2006). Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. Oncogene 25, 7305-7310.

79.  Foster DA. (2007). Regulation of mTOR by phosphatidic acid? Cancer Res. 67, 1-4.

80.  Foster DA. (2007). Drug resistance to rapamycin through elevated phospholipase D activity.  In “Cancer drug resistance research perspectives”. Nova Science Publisher, Inc. Chap IX, 139-145.

81.  Mor, A., Campi, G., Du, G., Zheng, Y., Foster, D.A., Dustin, M.L., and Philips, M., (2007). The lymphocyte function associated-1 receptor co-stimulates plasma membrane Ras via phospholipase D2. Nature Cell Biol. 9, 713-719.

82.  Shi, M., Zheng, Y., Garcia, A., and Foster, D.A. (2007). Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras. Cancer Lett, 258, 268-275.

83.  Gadir, N., Lee, E., Garcia, A., Toschi, A., and Foster, D.A. (2007). Suppression of TGF-b signaling by phospholipase D. Cell Cycle 6, 2840-2845 (Featured on Journal Cover).

84. Gadir, N., Jackson, D., Lee, E., and Foster, D.A. (2008). Defective TGF-β signaling sensitizes human cancer cells to rapamycin. Oncogene 27, 1055-1062.

85.  Toschi, A., Edelstein, J., Rockwell, P., Ohh, M., and Foster, D.A. (2008). HIFa expression in VHL deficient renal cell carcinoma cells is dependent on phospholipase D.  Oncogene, 27, 2746-2753.

86.  Garcia, A., Zheng, Y., Zhao, C., Toschi, A., Fan, J., Schreibman, N., Brown, H.A., Bar-Sagi, D., Foster, D.A.*, and Arbiser, J. (2008). Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells. Clinical Cancer Res. 14, 4267-4274. PMCID: PMC2759181 *Corresponding Author.

87.  Foster, D.A., and Gadir, N. (2008). Can defective TGF-b signaling be an Achilles heel in cancer? Chinese Journal of Cancer. 27, 882-884. (Invited Review)

88.  Thompson, S., Chen, X., Hui, L., Toschi, A. Foster, D.A., and Drain, C.M. (2008). Low Concentrations of a non-hydrolysable tetra-S-glycosylated porphyrin and low light induces apoptosis in human breast cancer cells via stress of the endoplasmic reticulum. Photochem Photobiol Sci. 7, 1415-1421.

89.  Toschi, A., Lee, E., Gadir, N., Ohh, M., and Foster, D.A. (2008). *Differential dependence of HIF1a and HIF2a on mTORC1 and mTORC2. J. Biol. Chem. 283, 34495-34499. PMCID: PMC2596400 *Accelerated Publication

90.  Toschi A, Lee E, Xu L, Garcia A, Gadir N, and Foster DA. (2009). Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid – a competition with rapamycin. Mol. Cell. Biol. 29, 1411-1420. PMCID: PMC2648237

91.  Foster DA, and Toschi A. (2009). Targeting mTOR with Rapamycin: One dose does not fit all. Cell Cycle. 8, 1026-1029. PMCID: PMC2778016 (Invited Review)

92. Foster DA. (2009). Phosphatidic acid signaling to mTOR: Signals for the survival of human cancer cells.  Biochem. Biophys. Acta. 1791, 949-955. PMCID: PMC2759177 (Invited Review)

93. Foster DA, and Darnell JE Jr. Obituary: Hidesaburo Hanafusa (1929-2009) (2009). Nature. 458, 718.

94. Roberts AM, Watson IR, Evans AG, Foster DA, Irwin MS, and Ohh M. (2009). Suppression of HIF2a Restores p53 activity via HDM2 and reverses chemoresistance of renal carcinoma cells. Cancer Res. 69, 9056-9064. PMCID: PMC2789194

95. Foster DA. (2010). Reduced mortality and moderate alcohol consumption: The phospholipase D-mTOR connection. Cell Cycle. 9, 1291-1294. PMCID: PMC2957519

96. Lyo D, Xu L, and Foster DA. (2010). Phospholipase D stabilizes HDM2 through an mTORC2/SGK1 pathway. Biochem. Biophys. Res. Comm. 396, 562-565. PMCID: PMC3010228

97. Toschi A, Lee E, Thompson S, Gadir N, Yellen P, Drain CM, Ohh M, and Foster DA. (2010). Phospholipase D-mTORC2 requirement for the Warburg effect in human cancer cells. Cancer Lett. 299, 72-79. PMCID: PMC3010225

98. Foster DA, Yellen P, Xu L. and Saqcena M. (2010). Regulation of G1 cell cycle progression:  Distinguishing the restriction point from a nutrient-sensing cell growth checkpoint. Genes and Cancer. 1, 1124-1131. PMCID: PMC3092273

99. Xu L, Salloum D, Saqcena M, Yellen P, Medlin PS, Perrella B, and Foster DA. (2011). Phospholipase D mediates nutrient input to mTORC1. J. Biol. Chem. 286, 25477-25486. PMCID: PMC3138251

100. Yellen P, Saqcena M, Salloum D, Feng J, Preda A, Xu L, Rodrik-Outmezguine V, and Foster DA. (2011). High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1. Cell Cycle 10, 3948-3956. PMCID: PMC3266120

101. Yellen P, Chatterjee A, Preda A, and Foster DA. (2013). Inhibition of S6 kinase suppresses the apoptotic effect of eIF4E ablation by inducing TGF-b-dependent G1 cell cycle arrest. Cancer Lett. 333, 239-243. PMCID: PMC3640435

102. LeGendre O, Sookdeo A, Duliepre S-A, Utter M, Frias M, and Foster DA. (2013). Suppression of AKT phosphorylation restores rapamycin-mediated synthetic lethality in SMAD4-defective pancreatic cancer cells. Mol Cancer Res. 11, 474-481. PMCID: PMC3640435

103. Einbond LS, Mighty J, Kasiwazaki R, Figueroa M, Jalees F, Acuna UM, LeGendre O, Foster DA, Kennelly EG. (2013). Garcinia benzophenones inhibit the growth of human colon cancer cells and synergize with sulindac sulfide and turmeric. Anti-Cancer Agents Med Chem. .

104. Foster DA. (2013). Phosphatidic acid and lipid sensing by mTOR. Trends Endocrin Metab 24, 272-278. PMCID: PMC3669661

105. Saqcena M, Menon D, Patel D, Mukhopadhyay S, Chow V, and Foster DA. (2013).  Distinct nutrient-dependent metabolic checkpoints in mammalian G1 cell cycle. PLoS-One. 8, e71457. PMCID: PMC3747087

106. LeGendre O, Sookdeo A, and Foster DA. (2014). BxPC3 pancreatic cancer cells express a truncated Smad4 protein upon PI3K and mTOR inhibition. Oncology Lett. 7, 1165-1168. PMCID: PMC3961292

107. Salloum D, Mukhopadhyay S, Tung K, Polonetskaya A, and Foster DA. (2014). Mutant Ras elevates dependence on serum lipids and creates a synthetic lethality for rapamycin. Mol Cancer Ther. 13, 733-741. PMCID: PMC4001122

108. Foster DA, Salloum D, Menon D, and Frias M. (2014). Phospholipase D and the maintenance of phosphatidic acid levels for regulation of mTOR. J Biol Chem. 289, 22583-22588. PMCID: PMC4132766

109. Yellen P, and Foster DA. (2014). Inhibition of fatty acid synthase induces pro-survival Akt and ERK activation in K-RAS mutant cancer cells. Cancer Lett. 353, 258-263. PMCID: PMC4170853

110. Foster DA. (2014). Obituary: Geoffrey Louis Zubay (1931-2014): Pioneer in cell-free gene expression studies and molecular genetics. Trends Biochem Sci. 39, 505-506. PMCID: PMC3669661

111. Foster DA. (2014). Metabolic vulnerability of K-Ras-driven cancer cells. Mol Cell Oncology. 1, e963445. PMCID:PMC4655600

112. Saqcena M, Mukhopadhyay S, Hosny, C, Alhamed AA, Chatterjee A, and Foster DA. (2015).  Blocking anaplerotic entry of glutamine to TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs. Oncogene. 34, 2672-2680. PMCID: PMC4418945 Epub Jul 2014.

113. LeGendre O, Breslin P, and Foster DA. (2015). Oleocanthal rapidly and selectively induces cell death in cancer cells via lysosomal membrane permeabilization (LMP). Mol Cell Oncology. 2, e1006077. PMCID: PMC4568762

114. Mukhopadhyay S, Saqcena M, Chatterjee A, Garcia A, Frias MA, and Foster, DA. (2015). Reciprocal regulation of AMPK and phospholipase D. J Biol Chem. 290, 6986-6993. PMCID: PMC4358122

115. Chatterjee A, Mukhopadhyay S, Tung K, Patel D, and Foster DA. (2015).  Rapamycin employs TGF-β and Rb pathways to cause cell cycle arrest. Cancer Lett. 360, 134-140. PMCID: PMC4415112

116. Saqcena, M, Patel D, Menon D, Mukhopadhyay S, and Foster DA. (2015). Apoptotic effects of high dose rapamycin occur in S-phase of the cell cycle. Cell Cycle. 14, 2285-2292. PMCID: PMC4614271

117. Foster DA, and Menon D. (2015). Phospholipase D. Encyclopedia of Cancer. In Press.

118. Mukhopadhyay S, Chatterjee A, Kogan D, Patel D, and Foster, DA. (2015). 5-Aminoimidazole-4-carboxamide-1-β-4-ribofuranoside (AICAR) enhances the efficacy of rapamycin in human cancer cells. Cell Cycle, 14, 3331-3339. PMCID: PMC4825547

119. Mukhopadhyay S, Saqcena M, and Foster DA. (2015). Synthetic lethality in KRas-driven cancer cells created by glutamine deprivation. Oncoscience, 2, 807-808. PMCID: PMC4671930

120.  Mukhopadhyay S, Frias MA, Chatterjee A, Yellen P, and Foster DA. (2016). The enigma of rapamycin dosage. Mol Cancer Ther. 15, 347-353. PMCID: PMC4783198

121. Patel D, Menon D, Bernfeld S, Mroz V, Kalan S, Loayza D, Foster DA. (2016). Aspartate rescues S-phase arrest caused by suppression of glutamine utilization in KRas-driven cancer cells. J. Biol Chem. 291, 9322-9329. PMCID: PMC4861495

 

Last Updated ( Monday, 27 June 2016 12:28 )